Evidence map›Paper›PMID 28384505›Full record

SynthesisInternational journal for parasitology. Drugs and drug resistance2017

The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials.

R J Commons, K Thriemer, G Humphreys, I Suay, C H Sibley, P J Guerin, R N Price

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal for parasitology. Drugs and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 12 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 12 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Trial
  15. Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  16. Effect of higher dose primaquine for the radical cure ofThe Lancet regional health. Western Pacific · 2026
    Article
  17. Investigation of Mutations in theMicroorganisms · 2024
    Article
  18. Article
  19. Review
  20. Basic Research ofFrontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

R J CommonsGlobal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia; WorldWide Antimalarial Resistance Network, UK. Electronic address: robert.commons@gmail.com.
K ThriemerGlobal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
G HumphreysWorldWide Antimalarial Resistance Network, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
I SuayWorldWide Antimalarial Resistance Network, UK.
C H SibleyWorldWide Antimalarial Resistance Network, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Department of Genome Sciences, University of Washington, Seattle, USA.
P J GuerinWorldWide Antimalarial Resistance Network, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
R N PriceGlobal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia; WorldWide Antimalarial Resistance Network, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Angkor Hospital for Children · KHCharles Darwin University · AUUniversity of Washington · USWorldwide Veterinary Service · GB

Funding

Wellcome Trust 200909Wellcome Trust 200909/Z/16/Z
6 · The paper itself

Abstract

introductionRecurrent P. vivax infections are associated with significant morbidity and mortality. Although radical cure can reduce recurrent infection, it is confounded by antimalarial resistance and the lack of safe and effective hypnozoitocidal treatment. This study documents the available literature of published clinical trials of P. vivax, providing an up to date, online, open access tool to view and download available information.

methodsA systematic review was conducted according to PRISMA guidelines to identify prospective P. vivax therapeutic clinical trials with at least 28 days follow-up published between 1st January 1960 and 12th October 2016. Treatment arms and evidence of chloroquine resistance were mapped to trial sites.

resultsSince 1960, a total of 1152 antimalarial clinical trials with a minimum 28 days follow-up have been published, of which 230 (20.0%) enrolled patients with P. vivax and were included. Trials were conducted in 38 countries: 168 (73.0%) in the Asia-Pacific, 13 (5.7%) in Africa and 43 (18.7%) in the Americas. The proportion of antimalarial trials assessing P. vivax rose from 10.7% (12/112) in 1991-1995, to 24.9% (56/225) in 2011-2015. Overall, 188 (81.7%) P. vivax trials included a chloroquine treatment arm, either alone or in combination with primaquine, and 107 (46.5%) trials included a chloroquine treatment arm with early primaquine to assess radical cure. There has been a recent increase in treatment arms with artemisinin derivatives. Of the 131 sites in which chloroquine resistance could be quantified, resistance was present in 59 (45.0%) sites in 15 endemic countries.

conclusionsOver the last 20 years there has been a substantial increase in clinical research on the treatment of P. vivax, which has generated a greater awareness of the global extent of chloroquine resistance. The WWARN open access, online interactive map provides up to date information of areas where drug resistant P. vivax is emerging.

Indexed as

Clinical Trials as TopicDatabases, FactualOnline SystemsAfricaAmericasAntimalarialsAsiaChloroquineDrug ResistanceHumansMalaria, VivaxAntimalarialsChloroquineClinical trialOpen accessPlasmodium vivaxResistanceReviewTreatment

Identifiers

PMID28384505
PMCPMC5382033
OpenAlexW2601167491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.